In the IQVIA Use of Medicines in the US 2024 report, biosimilars were found to be large contributors to lower drug costs and drivers of market growth; however, these products account for about 23% of the overall biologics market, showing wide variation in uptake across molecules.
Despite contributing significantly to reduced drug costs and market growth, biosimilars account for only about 23% of the overall biologics market, showing wide variation in uptake across different molecules, according to the IQVIA Use of Medicines in the US report.
This annual trend report aimed to advance knowledge by examining health system recovery, changes in medicine use, drug pricing, out-of-pocket costs, and the impact of biosimilars and new medicines on future drug spending.
Overall, specialty medicines accounted for 54% of spending in 2023, up from 49% in 2018, driven by growth in immunology and oncology. Traditional therapies gained share due to increased spending on diabetes and obesity medications, as well as vaccines. The median annual treatment cost of new medicines launched in 2023 exceeded $150,000, with oncology and rare disease treatments approaching $300,000 per patient.
Total spending grew by $10.4 billion, driven by $19 billion on new brands and a $22 billion shift toward higher-value medicines, offset by a $28 billion decline in COVID-19 spending and $17 billion due to expiries. Protected brand net prices rose by 3.0%, excluding significant price reductions for off-patent brands like adalimumab. Biosimilars saw an average volume uptake of over 50% within the first year.
The uptake of biosimilars with at least 3 years on the market varied widely, ranging from 8% for insulin lispro to 82% for bevacizumab. By the end of 2023, biosimilars for adalimumab (Humira) had achieved just 2% of volume, likely due to the originator's contracts with insurers and differences in biosimilar formulations compared to the widely used citrate-free high potency forms from the originator. Biosimilars for ranibizumab (Lucentis), launched in July 2022, accelerated to 45% uptake by 17 months.
Over the next 5 years, list price spending is expected to grow by 6% to 9%, while manufacturer net revenues will increase by 4% to 7%, influenced by price negotiations and the Inflation Reduction Act. New brand spending is projected to reach $122 billion, down from $149 billion in the previous 5 years, with net prices for protected brands declining by 1% to 4%.
Most of the losses from exclusivity between 2020 and 2022 came from new biosimilars, especially in oncology with bevacizumab, rituximab, and trastuzumab. In 2023, biologic brand losses grew, mainly because adalimumab saw major net sales declines due to extra discounts and rebates, resulting in only a 2% volume loss to eight new biosimilar competitors.
The report predicted that loss of exclusivity for biologics and small generics will result in $93.6 billion in spending reductions by 2028. Growth will be driven by oncology and obesity, while diabetes, immunology, and COVID-19 will contribute to a slowdown.
Biologic brand losses are expected to exceed $60.8 billion due to earlier biosimilar events and significant losses of exclusivity in 2024 and 2025 for products like natalizumab (Tysabri), tocilizumab (Actemra), denosumab (Prolia/Xgeva), insulin aspart (Novolog), and ustekinumab (Stelara). Later, biosimilar introductions for PD-1/PD-L1 therapies nivolumab (Opdivo) and pembrolizumab (Keytruda) will further reduce brand spending in oncology.
Obesity drug spending has surged due to popular GLP-1 inhibitors and could rise further with broader reimbursement. Diabetes spending will remain flat as novel therapies are offset by price cuts. Immunology growth will slow to 2% to 5% due to biosimilars, with a 75% volume increase. Sales for next-generation biotherapeutics, including cell and gene therapies and RNA therapies, are expected to reach $18 billion by 2028, over 3.5 times the current level.
Reference
The use of medicines in the U.S. 2024: Usage and spending trends and outlook to 2028. IQVIA. May 7, 2024. Accessed May 22, 2024. https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/the-use-of-medicines-in-the-us-2024
The Rebate War: How Originator Companies Are Fighting Back Against Biosimilars
November 25th 2024Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by increasing rebates and lowering net prices, despite short approval-to-launch timelines for biosimilars.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Overcoming Challenges to Improve Access and Reduce Costs
November 12th 2024Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but realizing this potential will require urgent policy reforms, market competition, and better education for both providers and patients.
Challenges, Obstacles, and Future Directions for Anti-TNF Biosimilars in IBD
November 9th 2024A review article on tumor necrosis factor (TNF)-α inhibitors in inflammatory bowel disease (IBD) outlined current use of anti-TNF originators and biosimilars, their efficacy and safety, the benefits and challenges of biosimilars, and the future of biosimilars in IBD.
The Rebate War: How Originator Companies Are Fighting Back Against Biosimilars
November 25th 2024Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by increasing rebates and lowering net prices, despite short approval-to-launch timelines for biosimilars.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Overcoming Challenges to Improve Access and Reduce Costs
November 12th 2024Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but realizing this potential will require urgent policy reforms, market competition, and better education for both providers and patients.
Challenges, Obstacles, and Future Directions for Anti-TNF Biosimilars in IBD
November 9th 2024A review article on tumor necrosis factor (TNF)-α inhibitors in inflammatory bowel disease (IBD) outlined current use of anti-TNF originators and biosimilars, their efficacy and safety, the benefits and challenges of biosimilars, and the future of biosimilars in IBD.
2 Commerce Drive
Cranbury, NJ 08512